Revenio Oyj : annual reporting package 2023 has been published
March 12, 2024 at 03:08 am EDT
Share
English
Finnish
Published: 2024-03-12 08:00:00 CET
Revenio Group Corporation
Annual Financial Report
Revenio's annual reporting package 2023 has been published
Revenio Group Corporation | Stock Exchange Release | March 12, 2024 at 09:00:00 EET
Revenio Group Corporation has published its annual reporting package for 2023. The annual reporting package comprises of Report by the Board of Directors, Financial Statements and Auditor's Report, Sustainability Report, Corporate Governance Statement and Remuneration Report.
The reports are attached to this release and are also available to read and download in Finnish and English on the company's website as separate pdf files:
www.reveniogroup.fi/fi/sijoittajat/raportit_ja_esitykset (in Finnish)
www.reveniogroup.fi/en/investors/reports_and_presentations (in English)
Revenio's Financial Statements in accordance with European Single Electronic Format (ESEF) reporting requirements are published in Finnish and English. In line with the ESEF requirements, the primary statements and notes to the financial statements have been labelled with XBRL tags. The audit firm Deloitte Oy has provided an independent auditor's reasonable assurance report on Revenio's ESEF financial statements.
Revenio does not publish a printed annual report.
Revenio Group Corporation
Board of Directors
For further information, please contact
CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi
Distribution
Nasdaq Helsinki Ltd
Main media
www.reveniogroup.fi/en
Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand.
In 2023, the Group's net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
Attachments:
reveniogroup-2023-12-31-en.zip
Revenio Group Corporation Corporate Governance Statement 2023.pdf
Revenio Group Corporation Remuneration Report 2023.pdf
Revenio Group Corporation Report by the Board of Directors and Financial Statements 2023.pdf
Revenio Group Corporation Sustainability Report 2023.pdf
This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page
Attachments
Original Link
Permalink
Disclaimer
Revenio Group Oyj published this content on
12 March 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
12 March 2024 07:07:08 UTC.
Revenio Group Oyj, formerly Done Solutions Oyj, is a Finland-based company primarily engaged in the health technology segment. The Companyâs activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. It distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.